Steven L. Stroup

Dr. Steven L. Stroup, one of the founders of Bach Pharma, Inc, is currently serving as Chairman of the Board of Directors and as Chief Medical Officer. He is responsible for the overall direction of the company, and is involved in all ongoing studies relating to the Company’s Research and Development as the Director of U.S. Medical Research. Dr. Stroup provides medical oversight, expertise and leadership in the implementation of clinical trial programs. He works very closely with Bach Pharma’s Officers, Directors and Advisors as the company pursues its intensified focus on bringing Bach’s drug platform through to an Investigational New Drug (IND) for the therapeutic treatment of Gulf War Illness (GWI), as well as new, urgently needed therapeutics to help treat patients affected by the COVID-19 pandemic.

Dr. Stroup was a founder and past board member of both Protherics Limited (formerly Therapeutic Antibodies Inc.) and BSD Medical Inc. He is also a past member of the Board of Governors of the Hospital Corporation of America. Dr. Stroup retired as the Director of Radiation Oncology at Sarah Cannon Cancer Center in Nashville, since renamed PearlPoint Cancer Support Foundation Center, which he founded, and has been the Chairman and a Director of the Nashville-Davidson County Unit of the American Cancer Society. The PearlPoint Cancer Support Foundation Center, is a non-profit organization committed to providing guidance to cancer patients.

Dr. Stroup received his MD at the University of Illinois. He completed his residency in Radiation Oncology at Duke University Hospital. Dr. Stroup served as Major in the United States Air Force at Keesler Medical Center. He also served as Director of the Division of Radiation Oncology at Vanderbilt University, and he holds a degree in Marketing and Management from Southern Illinois University.

No stranger to military life, Dr. Stroup previously served as Major in the United States Air Force, at Keesler Medical Center. Stroup reported, “We are very proud of our results on the Department of Defense study on Gulf War Illness (GWI), and plan on completing studies with the U.S. Department of Veterans Affairs.” In addition to GWI and other neuroimmunodegenerative diseases, Dr. Stroup continues to maintain interests in research in oncology, chemotherapy, radiation and closed head trauma.